Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 30   

Articles published

PSTI 3.40 +0.02 (0.59%)
price chart
Pluristem to Deliver Key Commercialization and Scientific Presentations at ...
HAIFA, Israel, April 16, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Dr.
Related articles »  
Pluristem Scientists to Present a Poster on GvHD & Participate in a Panel ...
HAIFA, Israel, March 25, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced its participation in the 2nd UK-Israel Regenerative Medicine Conference ...
Related articles »  
Inflammatory Bowel Disease Market - Global Industry Analysis, Size, Share ...
... Baxter International, Inc., Johnson & Johnson, Sequella, Inc., Sanofi-Aventis LLC, Osiris Therapeutics, Inc., AstraZeneca PLC, Eisai Co.
UK's Minister for Universities and Science, David Willetts & His Delegation ...
HAIFA, Israel, March 26, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that a delegation from the UK made an official visit to Pluristem on March ...
Related articles »  
US stocks rise as jobless claims retreat to three-month low
Brands Inc. gained 3.3 percent after Robert W. Baird & Co. raised the stock's rating. Pluristem Therapeutics Inc. climbed 4.2 percent after getting regulatory approval for manufacturing stem-cell therapy products.